263 related articles for article (PubMed ID: 18200805)
1. Atherogenic lipid profiles and its management in patients with rheumatoid arthritis.
Nurmohamed MT
Vasc Health Risk Manag; 2007; 3(6):845-52. PubMed ID: 18200805
[TBL] [Abstract][Full Text] [Related]
2. Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis.
Naerr GW; Rein P; Saely CH; Drexel H
Vascul Pharmacol; 2016 Jun; 81():22-30. PubMed ID: 26903239
[TBL] [Abstract][Full Text] [Related]
3. Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy.
Curtis JR; John A; Baser O
Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1282-91. PubMed ID: 22504829
[TBL] [Abstract][Full Text] [Related]
4. Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology.
Hollan I; Ronda N; Dessein P; Agewall S; Karpouzas G; Tamargo J; Niessner A; Savarese G; Rosano G; Kaski JC; Wassmann S; Meroni PL
Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):104-114. PubMed ID: 31397840
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Risk Assessment and Therapeutic Implications in Rheumatoid Arthritis.
Halacoglu J; Shea LA
J Cardiovasc Transl Res; 2020 Oct; 13(5):878-890. PubMed ID: 32080804
[TBL] [Abstract][Full Text] [Related]
6. The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis.
van Sijl AM; Peters MJ; Knol DL; de Vet RH; Sattar N; Dijkmans BA; Smulders YM; Nurmohamed MT
Semin Arthritis Rheum; 2011 Dec; 41(3):393-400. PubMed ID: 21665247
[TBL] [Abstract][Full Text] [Related]
7. Management of dyslipidaemia in high-risk patients with recent-onset rheumatoid arthritis: targets still not met despite specific recommendations. Results from the ESPOIR cohort during the first five years of follow-up.
Tournadre A; Pereira B; Dubost JJ; Rincheval N; Rat AC; Combe B; Soubrier M
Clin Exp Rheumatol; 2017; 35(2):296-302. PubMed ID: 28079508
[TBL] [Abstract][Full Text] [Related]
8. Lipids and lipid changes with synthetic and biologic disease-modifying antirheumatic drug therapy in rheumatoid arthritis: implications for cardiovascular risk.
Myasoedova E
Curr Opin Rheumatol; 2017 May; 29(3):277-284. PubMed ID: 28207495
[TBL] [Abstract][Full Text] [Related]
9. The lipid paradox in rheumatoid arthritis: the dark horse of the augmented cardiovascular risk.
Venetsanopoulou AI; Pelechas E; Voulgari PV; Drosos AA
Rheumatol Int; 2020 Aug; 40(8):1181-1191. PubMed ID: 32524301
[TBL] [Abstract][Full Text] [Related]
10. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis.
Nurmohamed MT; van Halm VP; Dijkmans BA
Drugs; 2002; 62(11):1599-609. PubMed ID: 12109923
[TBL] [Abstract][Full Text] [Related]
12. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis.
Popa C; van den Hoogen FH; Radstake TR; Netea MG; Eijsbouts AE; den Heijer M; van der Meer JW; van Riel PL; Stalenhoef AF; Barrera P
Ann Rheum Dis; 2007 Nov; 66(11):1503-7. PubMed ID: 17472994
[TBL] [Abstract][Full Text] [Related]
13. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis.
Vis M; Nurmohamed MT; Wolbink G; Voskuyl AE; de Koning M; van de Stadt R; Twisk JW; Dijkmans BA; Lems WF
J Rheumatol; 2005 Feb; 32(2):252-5. PubMed ID: 15693084
[TBL] [Abstract][Full Text] [Related]
14. Increased lipid levels but unchanged atherogenic index in rheumatoid arthritis patients treated with biologic disease modifying antirheumatic drugs: published experience.
Schimmel EK; Yazici Y
Clin Exp Rheumatol; 2009; 27(3):446-51. PubMed ID: 19604437
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of lipid phenotypes, serum lipid behaviour over follow-up and predictors of serum lipid levels in a cohort of Mexican Mestizo early rheumatoid arthritis patients treated with conventional disease-modifying anti-rheumatic drugs.
Sánchez T; Contreras-Yáñez I; Elías-López D; Aguilar Salinas CA; Pascual-Ramos V
Clin Exp Rheumatol; 2014; 32(4):509-15. PubMed ID: 25005131
[TBL] [Abstract][Full Text] [Related]
16. Conventional lipid profile and lipoprotein(a) concentrations in treated patients with rheumatoid arthritis.
García-Gómez C; Nolla JM; Valverde J; Gómez-Gerique JA; Castro MJ; Pintó X
J Rheumatol; 2009 Jul; 36(7):1365-70. PubMed ID: 19369465
[TBL] [Abstract][Full Text] [Related]
17. Are lipid ratios less susceptible to change with systemic inflammation than individual lipid components in patients with rheumatoid arthritis?
Toms TE; Panoulas VF; Douglas KM; Nightingale P; Smith JP; Griffiths H; Sattar N; Symmons DP; Kitas GD
Angiology; 2011 Feb; 62(2):167-75. PubMed ID: 20682616
[TBL] [Abstract][Full Text] [Related]
18. Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm.
Robertson J; Peters MJ; McInnes IB; Sattar N
Nat Rev Rheumatol; 2013 Sep; 9(9):513-23. PubMed ID: 23774906
[TBL] [Abstract][Full Text] [Related]
19. [Lipid profile and cardiovascular risk in patients with rheumatoid arthritis: Effect of the disease and of drug therapy].
Hansel B; Bruckert E
Ann Endocrinol (Paris); 2010 Sep; 71(4):257-63. PubMed ID: 20416859
[TBL] [Abstract][Full Text] [Related]
20. Effects of TNFα inhibitors on adiposity and other cardiovascular risk factors: implications for the cardiovascular prognosis in patients with rheumatoid arthritis.
Toussirot É
Expert Opin Drug Saf; 2015 Apr; 14(4):525-32. PubMed ID: 25599626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
